Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-08-13
DOI
10.3389/fimmu.2020.01727
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Challenges in treating Pompe disease: an industry perspective
- (2019) Hung V. Do et al. Annals of Translational Medicine
- Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review
- (2019) Ankit K. Desai et al. Annals of Translational Medicine
- Methotrexate and BAFF interaction prevents immunization against TNF inhibitors
- (2018) Samuel Bitoun et al. ANNALS OF THE RHEUMATIC DISEASES
- Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution
- (2018) Keith A Sacco et al. Immunotherapy
- High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy
- (2018) Esther Poelman et al. JOURNAL OF PEDIATRICS
- An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease
- (2018) Zoheb B. Kazi et al. GENETICS IN MEDICINE
- Methotrexate BAFFles anti-drug antibodies
- (2018) Bruce N. Cronstein Nature Reviews Rheumatology
- Author Correction: Lysosomal storage diseases
- (2018) Frances M. Platt et al. Nature Reviews Disease Primers
- Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum
- (2017) David F. Kronn et al. PEDIATRICS
- Suppression of normal immune responses after treatment with rituximab
- (2016) Ruba Kado et al. CURRENT OPINION IN RHEUMATOLOGY
- Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes
- (2016) Chia-Feng Yang et al. JOURNAL OF PEDIATRICS
- Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction
- (2016) Priya S. Kishnani et al. MOLECULAR GENETICS AND METABOLISM
- Diverse effects on vaccine-specific serum IgG titres and memory B cells upon methotrexate and anti-TNF-α therapy in children with rheumatic diseases: A cross-sectional study
- (2016) Hanna M. Ingelman-Sundberg et al. VACCINE
- The role of antibodies in enzyme treatments and therapeutic strategies
- (2015) Brian W. Bigger et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy
- (2015) Kathryn L. Berrier et al. GENETICS IN MEDICINE
- Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long?
- (2015) Sara Barmettler et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome
- (2015) M. Colucci et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders
- (2015) Giancarlo Parenti et al. MOLECULAR THERAPY
- Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?
- (2015) Jennifer Worch et al. Cancers
- The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE
- (2014) L Watson et al. LUPUS
- Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
- (2014) R. C. Dale et al. NEUROLOGY
- Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis
- (2014) Stephanie Glaesener et al. Arthritis & Rheumatology
- Rituximab and Immune Deficiency: Case Series and Review of the Literature
- (2014) Blanka Kaplan et al. Journal of Allergy and Clinical Immunology-In Practice
- B-Cell Depletion and Immunomodulation before Initiation of Enzyme Replacement Therapy Blocks the Immune Response to Acid Alpha-Glucosidase in Infantile-Onset Pompe Disease
- (2013) Melissa E. Elder et al. JOURNAL OF PEDIATRICS
- Lysosomal storage diseases—the horizon expands
- (2013) Rose-Mary Naaman Boustany Nature Reviews Neurology
- Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT
- (2013) Suhrad G. Banugaria et al. PLoS One
- Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience
- (2012) Deeksha S. Bali et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS
- Enzyme Replacement Therapy for Lysosomal Diseases: Lessons from 20 Years of Experience and Remaining Challenges
- (2012) R.J. Desnick et al. Annual Review of Genomics and Human Genetics
- Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
- (2012) Yoav H. Messinger et al. GENETICS IN MEDICINE
- The emerging phenotype of long-term survivors with infantile Pompe disease
- (2012) Sean N. Prater et al. GENETICS IN MEDICINE
- Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology
- (2012) Jordan S. Orange et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Rituximab resistance
- (2011) Andrew R. Rezvani et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
- (2011) Suhrad G. Banugaria et al. GENETICS IN MEDICINE
- Atypical immunologic response in a patient with CRIM-negative Pompe disease
- (2011) Mary-Alice Abbott et al. MOLECULAR GENETICS AND METABOLISM
- Rituximab efficiency in children with steroid-dependent nephrotic syndrome
- (2010) Anne-Laure Sellier-Leclerc et al. PEDIATRIC NEPHROLOGY
- Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease
- (2010) Michael Beck Therapeutics and Clinical Risk Management
- Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
- (2009) Marc Nicolino et al. GENETICS IN MEDICINE
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
- (2009) Priya S. Kishnani et al. MOLECULAR GENETICS AND METABOLISM
- Elimination of Antibodies to Recombinant Enzyme in Pompe's Disease
- (2009) Nancy J. Mendelsohn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children
- (2009) Koichi Kamei et al. PEDIATRIC NEPHROLOGY
- Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease
- (2009) Priya S Kishnani et al. PEDIATRIC RESEARCH
- A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation
- (2008) V. Zarkhin et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias
- (2007) Aarati Rao et al. PEDIATRIC BLOOD & CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started